Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poliovirus type 2 capsid protein VP1 (VP1)
- Target
- VP1
- Molecular classification
- Viral capsid protein, structural protein
01
Overview
Poliovirus type 2 capsid protein VP1 is a structural viral protein that is not a traditional therapeutic target. It is a component of the poliovirus capsid that plays essential roles in viral stability, receptor recognition, and cell entry. While VP1 is not suitable for classification as a drug target, it is of significant interest in vaccine development, antiviral research, and understanding viral pathogenesis. The distinction is important: VP1 mutations affect viral phenotype rather than serving as druggable molecules for treating host disease.
- Other names
- VP1Capsid protein VP1Structural protein VP1
02
Mechanism of action
Capsid-binding drugs, such as pleconaril, interact with the hydrophobic pocket region of VP1. This interaction can affect capsid stability and conformational changes, thereby interfering with viral replication and entry.
03
Biological functions
Structural protein: Forms the rigid icosahedral shell that protects the viral RNA genomeReceptor binding: Participates in receptor-mediated cell entry through conformational changesCapsid stability: Maintains the metastable state of the virion that is critical for infectivity and cell entryGenome protection: Encapsidates and protects the single-stranded positive-sense RNA genome (~7500 nucleotides)
04
Disease associations
Poliomyelitis (caused by poliovirus infection)
05
Safety considerations
Viral escape and drug resistanceMutations in VP1 can alter thermal stability of the capsid, receptor binding and cell entry efficiency, sensitivity to capsid-binding antiviral compounds, and ability to establish persistent infectionVP1 mutations have been associated with mouse adaptation and altered virulence in some contexts
06
Interacting drugs
Pleconaril
Beyond the preview
Go deeper on Poliovirus type 2 capsid protein VP1 (VP1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Poliovirus type 2 capsid protein VP1 (VP1).